CAESAR's legacy: a new era of rigor in preclinical studies of cardioprotection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): a small animal acute myocardial infarction randomized-controlled multicenter study on the effect of ischemic preconditioning.Basic research in cardiology · 2025
   Article
2. The IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT): multicenter pig study on the effect of ischemic preconditioning.Basic research in cardiology · 2024
   Article
3. CAESAR lives on with IMPACT: bringing rigor and relevance to cardioprotection research.Basic research in cardiology · 2024
   Article
4. Re-evaluation of the cardioprotective effects of cannabinoids against ischemia-reperfusion injury according to the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria.Frontiers in pharmacology · 2024
   Review
5. No robust reduction of infarct size and no-reflow by metoprolol pretreatment in adult Göttingen minipigs.Basic research in cardiology · 2023
   Article
6. PU.1 inhibition does not attenuate cardiac function deterioration or fibrosis in a murine model of myocardial infarction.Molecular and cellular biochemistry · 2023
   Article
7. Pathways for Cardioprotection in Perspective: Focus on Remote Conditioning and Extracellular Vesicles.Biology · 2023
   Review
8. Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.Pharmacological reviews · 2023
   Review
9. Kinetic Characteristics of Curcumin and Germacrone in Rat and Human Liver Microsomes: Involvement of CYP Enzymes.Molecules (Basel, Switzerland) · 2022
   Article
10. Preclinical multi-target strategies for myocardial ischemia-reperfusion injury.Frontiers in cardiovascular medicine · 2022
    Review
11. Single dose of synthetic microRNA-199a or microRNA-149 mimic does not improve cardiac function in a murine model of myocardial infarction.Molecular and cellular biochemistry · 2021
    Article
12. IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action.Basic research in cardiology · 2021
    Review

Corrections and comments

• Comment on
  Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?2021

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.